Efficacy and safety of itraconazole as empirical antifungal therapy in febrile neutropenic patients with hematologic malignancies: an open-lable, multicenter, observational trial in a Chinese cohort

被引:1
|
作者
Cheng Shu [1 ]
Zhou Jian-feng [2 ]
Zou Ping [3 ]
Huang Xiao-jun [4 ]
Jin Jie [5 ]
Shen Zhi-xiang [1 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Shanghai Ruijin Hosp, Dept Hematol, Shanghai 200025, Peoples R China
[2] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Hematol, Tongji Hosp, Wuhan 430030, Hubei, Peoples R China
[3] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Hematol, Wuhan 430030, Hubei, Peoples R China
[4] Peking Univ, Peoples Hosp, Dept Hematol, Beijing 100044, Peoples R China
[5] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Hematol, Hangzhou 310003, Zhejiang, Peoples R China
关键词
itraconazole; hematologic malignancy; febrile neutropenia; empirical therapy; LIPOSOMAL AMPHOTERICIN-B; CLINICAL-PRACTICE GUIDELINES; INFECTIOUS-DISEASES SOCIETY; PERSISTENT FEVER; CANCER-PATIENTS; AMERICA;
D O I
10.3760/cma.j.issn.0366-6999.2011.22.013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Invasive fungal infection (IFI) is a common and fatal complication in neutropenic patients with hematological malignancy. Empirical antifungal therapy is widely used in practice due to the difficulty of pathogens determination and illness of the hosts. The aim of this study was to evaluate the efficacy and safety of itraconazole as empirical antifungal therapy for persistent fever in neutropenic patients with hematologic malignancies. Methods Two hundred and seventy-four patients with hematologic malignancies who had suspected fungal infections were enrolled in 18 centers across China between April 2008 and April 2009. Empirical antifungal therapy with intravenous itraconazole 200 mg twice daily was given for the first two days, followed by 200 mg once daily for the next 12 days. Oral itraconazole solution was sequential for follow-up therapy if necessary. Five composite end points were evaluated for the response, which was more restrictive and adopted for the first time in such study in China. Results The intent-to-treat analysis included data from 274 patients (full analysis set, FAS), of whom 248 were included as the per-protocol population (PPS). As the composite end point of five indices was concerned, the overall response rate was 43.4%. Seperately, defervescence was achieved in 90% of patients in which 55.5% occured during neutropenia. The mean time to defervescence was 2.71 days. Absence of breakthrough IFI during drug administration or within the first 7 days after study completion was observed in 71.5% of patients. Fifty-five point five percent patients with IFI at baseline was successfully treated. Ninety point five percent patients survived for at least 7 days after completing the study. PPS analysis revealed that the duration of neutropenia >= 10 days was a statistically significant negative predictor for the response. The withdrawal rate due to drug-related toxicity or lack of efficacy was 11.0%. The incidence of adverse events was 22.6%, in which 11.6% was study drug related. The most frequent adverse events were mild to moderate liver toxicity. Conclusion ltraconazole shows desirable efficacy and safety as empirical antifungal therapy for febrile neutropenic patients with hematologic malignancies. Chin Med J 2011;124(22):3670-3675
引用
收藏
页码:3670 / 3675
页数:6
相关论文
共 50 条
  • [1] Efficacy and safety of micafungin versus intravenous itraconazole as empirical antifungal therapy for febrile neutropenic patients with hematological malignancies: a randomized, controlled, prospective, multicenter study
    Jeong, Seong Hyun
    Kim, Dae Young
    Jang, Jun Ho
    Mun, Yeung-Chul
    Choi, Chul Won
    Kim, Sung-Hyun
    Kim, Jin Seok
    Park, Joon Seong
    [J]. ANNALS OF HEMATOLOGY, 2016, 95 (02) : 337 - 344
  • [2] Efficacy and safety of micafungin versus intravenous itraconazole as empirical antifungal therapy for febrile neutropenic patients with hematological malignancies: a randomized, controlled, prospective, multicenter study
    Seong Hyun Jeong
    Dae Young Kim
    Jun Ho Jang
    Yeung-Chul Mun
    Chul Won Choi
    Sung-Hyun Kim
    Jin Seok Kim
    Joon Seong Park
    [J]. Annals of Hematology, 2016, 95 : 337 - 344
  • [3] Efficacy and safety of intravenous itraconazole as empirical antifungal therapy for persistent fever in neutropenic patients with hematological malignancies in Japan
    Kensuke Ohta
    Saori Nishiki Kosaka
    Yoshitaka Nakao
    Takeo Kumura
    Kiyomichi Hagihara
    Erina Sakamoto
    Shuichiro Okamoto
    Asao Hirose
    Yasutaka Aoyama
    Ryousuke Yamamura
    Yoshiki Hayashi
    Yukari Umemoto
    Yoshiki Terada
    Yasunobu Takeoka
    Takahiko Nakane
    Hideo Koh
    Masayuki Hino
    [J]. International Journal of Hematology, 2009, 89 : 649 - 655
  • [4] Efficacy and safety of intravenous itraconazole as empirical antifungal therapy for persistent fever in neutropenic patients with hematological malignancies in Japan
    Ohta, Kensuke
    Kosaka, Saori Nishiki
    Nakao, Yoshitaka
    Kumura, Takeo
    Hagihara, Kiyomichi
    Sakamoto, Erina
    Okamoto, Shuichiro
    Hirose, Asao
    Aoyama, Yasutaka
    Yamamura, Ryousuke
    Hayashi, Yoshiki
    Umemoto, Yukari
    Terada, Yoshiki
    Takeoka, Yasunobu
    Nakane, Takahiko
    Koh, Hideo
    Hino, Masayuki
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2009, 89 (05) : 649 - 655
  • [5] EFFICACY AND SAFETY OF MICAFUNGIN AS AN EMPIRICAL ANTIFUNGAL AGENT FOR FEBRILE NEUTROPENIC PATIENTS
    Park, J. S.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 415 - 415
  • [6] A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with Hematologic malignancies
    Bow, E. J.
    Rotstein, C.
    Noskin, G. A.
    Laverdiere, M.
    Schwarer, A. P.
    Segal, B. H.
    Seymour, J. F.
    Szer, J.
    Sanche, S.
    [J]. CLINICAL INFECTIOUS DISEASES, 2006, 43 (04) : 447 - 459
  • [7] Safety and efficacy of low-dose amphotericin B lipid complex for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies
    Subirà, M
    Martino, R
    Sureda, A
    Altés, A
    Briones, J
    Brunet, S
    Sierra, J
    [J]. METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2001, 23 (09): : 505 - 510
  • [8] Safety and efficacy of itraconazole compared to amphotericin B as empirical antifungal therapy for neutropenic fever in patients with haematological malignancy
    Schuler, Ulrich
    Bammer, Susanne
    Aulitzky, Walter E.
    Binder, Claudia
    Boehme, Angelika
    Egerer, Gerlinde
    Sandherr, Michael
    Schwerdtfeger, Rainer
    Silling, Gerda
    Wandt, Hannes
    Glasmacher, Axel
    Ehninger, Gerhard
    [J]. ONKOLOGIE, 2007, 30 (04): : 185 - 191
  • [9] Efficacy and Safety of Micafungin as an Empirical Antifungal Agent for Febrile Neutropenic Patients with Hematological Diseases
    Park, Joon Seong
    Kim, Dong Hwan
    Choi, Chul Won
    Jeong, Seong Hyun
    Choi, Jin-Hyuk
    Kim, Kihyun
    Kim, Seok Jin
    Jung, Chul Won
    Yang, Deok-Hwan
    Jang, Jun Ho
    [J]. ACTA HAEMATOLOGICA, 2010, 124 (02) : 92 - 97
  • [10] a Randomized, Controlled, Prospective Study for Efficacy of Micafungin Versus Itraconazole As Empirical Antifungal Therapy for Febrile Neutropenic Patients with Acute Leukemia
    Jeong, Seong Hyun
    Kim, Dae Young
    Jang, Jun Ho
    Mun, Yeung-Chul
    Kim, Sung-Hyun
    Choi, Chul Won
    Kim, Jin Seok
    Park, Joon Seong
    [J]. BLOOD, 2014, 124 (21)